{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T14:57:10Z","timestamp":1793717830416,"version":"4.6.1"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T00:00:00Z","timestamp":1605571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Japan Society for the Promotion of Science (JAPS) KAKENHI","award":["18K07786"],"award-info":[{"award-number":["18K07786"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To investigate the clinical significance of serum IL-18 levels for the diagnosis of systemic JIA (s-JIA) and to predict the disease course of s-JIA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Overall, 116 patients with s-JIA, 151 with other diseases and 20 healthy controls were analysed. Serum IL-18 levels were measured longitudinally in 41 patients with s-JIA from active phase through remission phase. Serum IL-18 levels were quantified via enzyme-linked immunosorbent assay and the results were compared with clinical features and the disease course of s-JIA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The serum IL-18 level cut-off value for differentiation of s-JIA from other diseases was 4800\u2009pg\/ml. In patients with a monocyclic course, serum IL-18 levels steadily decreased during the inactive phase and low levels were sustained during remission. In contrast, in patients with a chronic course, elevated serum IL-18 levels were sustained even during the inactive phase. In patients with a polycyclic course, serum IL-18 levels were elevated during disease flares and normalized during the inactive phase. The serum IL-18 level cut-off value for diagnosis of remission in s-JIA was 595\u2009pg\/ml,<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Serum IL-18 levels of &amp;gt;4800\u2009pg\/ml may be useful for differentiating between s-JIA and other diseases. Monitoring of serum IL-18 levels might be useful for predicting the disease course and assessing remission in s-JIA.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa634","type":"journal-article","created":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T11:10:49Z","timestamp":1599563449000},"page":"2421-2426","source":"Crossref","is-referenced-by-count":35,"title":["Clinical significance of interleukin-18 for the diagnosis and prediction of disease course in systemic juvenile idiopathic arthritis"],"prefix":"10.1093","volume":"60","author":[{"given":"Mao","family":"Mizuta","sequence":"first","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1077-7772","authenticated-orcid":false,"given":"Masaki","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Inoue","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Ikawa","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Nakagishi","sequence":"additional","affiliation":[{"name":"Department of Pediatric Rheumatology, Hyogo Prefectural Kobe Children\u2019s Hospital, Kobe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuhei","family":"Yasuoka","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunology, Aichi Children\u2019s Health and Medical Center, Obu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Iwata","sequence":"additional","affiliation":[{"name":"Department of Infection and Immunology, Aichi Children\u2019s Health and Medical Center, Obu, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Yachie","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,17]]},"reference":[{"key":"2021051418585845700_keaa634-B1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/gene.2012.3","article-title":"Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment","volume":"13","author":"Ravelli","year":"2012","journal-title":"Genes Immun"},{"key":"2021051418585845700_keaa634-B2","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1002\/art.21774","article-title":"Predictors of disease course and remission in systemic juvenile idiopathic arthritis: significance of early clinical and laboratory features","volume":"54","author":"Singh-Grewal","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2021051418585845700_keaa634-B3","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1038\/nrrheum.2011.68","article-title":"Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions","volume":"7","author":"Mellins","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"2021051418585845700_keaa634-B4","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"},{"key":"2021051418585845700_keaa634-B5","first-page":"2071","article-title":"Effective use of the recombinant interleukin 1 receptor antagonist anakinra in therapy resistant systemic onset juvenile rheumatoid arthritis","volume":"31","author":"Verbsky","year":"2004","journal-title":"J Rheumatol"},{"key":"2021051418585845700_keaa634-B6","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1056\/NEJMoa1205099","article-title":"Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis","volume":"367","author":"Ruperto","year":"2012","journal-title":"N Engl J Med"},{"key":"2021051418585845700_keaa634-B7","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/rheumatology\/keq133","article-title":"Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis","volume":"49","author":"Shimizu","year":"2010","journal-title":"Rheumatology"},{"key":"2021051418585845700_keaa634-B8","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.clim.2015.06.005","article-title":"Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis","volume":"160","author":"Shimizu","year":"2015","journal-title":"Clin Immunol"},{"key":"2021051418585845700_keaa634-B9","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.3899\/jrheum.140025","article-title":"Serum interleukin 18 as a diagnostic remission criterion in systemic juvenile idiopathic arthritis","volume":"41","author":"Shimizu","year":"2014","journal-title":"J Rheumatol"},{"key":"2021051418585845700_keaa634-B10","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1007\/s10067-006-0474-0","article-title":"Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis","volume":"26","author":"Jelusic","year":"2007","journal-title":"Clin Rheumatol"},{"key":"2021051418585845700_keaa634-B11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1546-0096-9-15","article-title":"Monitoring serum IL-18 levels is useful for treatment of a patient with systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome","volume":"9","author":"Shigemura","year":"2011","journal-title":"Pediatr Rheumatol Online J"},{"key":"2021051418585845700_keaa634-B12","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"2021051418585845700_keaa634-B13","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/acr.20497","article-title":"American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis","volume":"63","author":"Wallace","year":"2011","journal-title":"Arthritis Care Res"},{"key":"2021051418585845700_keaa634-B14","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.cyto.2013.09.007","article-title":"Sustained elevation of serum interleukin-18 and its association with hemophagocytic lymphohistiocytosis in XIAP deficiency","volume":"65","author":"Wada","year":"2014","journal-title":"Cytokine"},{"key":"2021051418585845700_keaa634-B15","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/ng.3089","article-title":"An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome","volume":"46","author":"Canna","year":"2014","journal-title":"Nat Genet"},{"key":"2021051418585845700_keaa634-B16","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.clim.2011.12.008","article-title":"Alternative activation in systemic juvenile idiopathic arthritis monocytes","volume":"142","author":"Macaubas","year":"2012","journal-title":"Clin Immunol"},{"key":"2021051418585845700_keaa634-B17","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.cyto.2012.05.003","article-title":"Compensated inflammation in systemic juvenile idiopathic arthritis: role of alternatively activated macrophages","volume":"60","author":"Shimizu","year":"2012","journal-title":"Cytokine"},{"key":"2021051418585845700_keaa634-B18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.cyto.2012.02.006","article-title":"Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: the diagnostic significance of interleukin-18 and interleukin-6","volume":"58","author":"Shimizu","year":"2012","journal-title":"Cytokine"},{"key":"2021051418585845700_keaa634-B19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/acr.23277","article-title":"Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis","volume":"70","author":"Schulert","year":"2018","journal-title":"Arthritis Care Res"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/5\/2421\/37935789\/keaa634.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/5\/2421\/37935789\/keaa634.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T18:59:30Z","timestamp":1621018770000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/5\/2421\/5983858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,17]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,11,17]]},"published-print":{"date-parts":[[2021,5,14]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa634","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2020,11,17]]}}}